This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

INfusion VErsus STimulation in Parkinson's Disease (INVEST)

This study is currently recruiting participants.
See Contacts and Locations
Verified January 2017 by J.M. Dijk, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor:
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by (Responsible Party):
J.M. Dijk, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier:
NCT02480803
First received: May 4, 2015
Last updated: January 31, 2017
Last verified: January 2017
  Purpose
Both Continuous intrajejunal Levodopa Infusion (CLI) and Deep Brain Stimulation (DBS) are accepted therapies for the treatment of advanced Parkinson's disease (PD). To date, no comparative studies have been executed. The INVEST study is an open label randomised controlled trial with cost-effectiveness as primary outcome. Secondary outcomes will be quality of life, neurological impairments, among others.

Condition Intervention Phase
Parkinson's Disease Drug: Continuous intrajejunal infusion of levodopa-carbidopa Device: deep brain stimulation Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulation

Resource links provided by NLM:


Further study details as provided by J.M. Dijk, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):

Primary Outcome Measures:
  • Cost effectiveness in costs per unit on PDQ-39 [ Time Frame: 12 months ]
    The costs per unit on the PDQ-39.

  • Cost-utility in costs per QALY [ Time Frame: 12 months ]
    The costs per QALY. The EQ-5D will be applied as the utility measure.


Secondary Outcome Measures:
  • Change from Baseline in quality of life: changes on PDQ-39 at 12 months [ Time Frame: 12 months ]
    Parkinson's Disease Questionnaire-39

  • Change from Baseline in quality of life: changes on EQ-5D [ Time Frame: 12 months ]
    EQ-5D questionnaire

  • Change from Baseline in motor symptoms: score changes in off and on state on MDS-UPDRS [ Time Frame: 12 months ]
    MDS-UPDRS part 3, motor symptom diary, clinical dyskinesia rating scale

  • Change from Baseline in motor symptoms: changes in off-state, on-state without dyskinesias, on-state without troublesome dyskinesias and on-state with troublesome dyskinesias [ Time Frame: 12 months ]
    measured with motor symptom diary

  • Change from Baseline in motor symptoms: changes on clinical Dyskinesia Rating Scale [ Time Frame: 12 months ]
    clinical dyskinesia rating scale

  • Change from Baseline in non-motor symptoms: changes on Non Motor Symptom Checklist [ Time Frame: 12 months ]
    Non Motor Symptom Checklist

  • Change from Baseline in non-motor symptoms: changes on Rotterdam Symptom Checklist [ Time Frame: 12 months ]
    Rotterdam Symptom Checklist

  • Change from Baseline in non-motor symptoms: changes on SCOPA-AUT [ Time Frame: 12 months ]
    SCOPA-AUT

  • Change from Baseline in non-motor symptoms: changes on MDS-UPDRS part 2 [ Time Frame: 12 months ]
    MDS-UPDRS part 2

  • Number of participants with adverse effects and description of adverse effects at 12 months [ Time Frame: 12 months ]
  • Number of participants with complications and description of complications at 12 months [ Time Frame: 12 months ]
  • Number of participants with treatment failure at 12 months [ Time Frame: 12 months ]
  • Number of participants who stopped treatment at 12 months [ Time Frame: 12 months ]
  • Number of participants with treatment cross-over at 12 months [ Time Frame: 12 months ]
  • Change from Baseline in PD-medication (levodopa-equivalent dose) at 12 months [ Time Frame: 12 months ]
    levodopa-equivalent dose

  • Change from Baseline in disability: change of Hoehn and Yahr stage [ Time Frame: 12 months ]
    Hoehn and Yahr stage

  • Change from Baseline in functional health status: changes on AMC Linear Disability Score) [ Time Frame: 12 months ]
    The AMC Linear Disability Score

  • Change from Baseline in patient satisfaction (questionnaire) [ Time Frame: 12 months ]
    questionnaire

  • Change from Baseline in patients attitude to treatment on PRO-Likert Scale [ Time Frame: 12 months ]
    PRO-Likert Scale

  • Change from Baseline in cognition: changes on Mattis Dementia Rating Score [ Time Frame: 12 months ]
    Neuropsychologic assessment: Mattis Dementia Rating Score

  • Change from Baseline in cognition: changes on PD-CRS [ Time Frame: 12 months ]
    Neuropsychologic assessment: Parkinson's Disease- Cognitive Rating Scale

  • Change from Baseline in language: changes on Boston Naming Test [ Time Frame: 12 months ]
    Neuropsychologic assessment: Dutch version of Boston Naming Test

  • Change from Baseline in language: changes on letter fluency test [ Time Frame: 12 months ]
    Neuropsychologic assessment: Dutch version of letter fluency test

  • Change from Baseline in intelligence: changes on WAIS IV [ Time Frame: 12 months ]
    Neuropsychologic assessment: WAIS IV

  • Change from Baseline in intelligence: changes on Dutch Reading test for Adults [ Time Frame: 12 months ]
    Neuropsychologic assessment: Dutch Reading test for Adults

  • Change from Baseline in memory: changes on 15 word test [ Time Frame: 12 months ]
    Neuropsychologic assessment: Dutch 15 word test

  • Change from Baseline in memory: changes on Rivermead Behavioral Memory Test [ Time Frame: 12 months ]
    Neuropsychologic assessment: Rivermead Behavioral Memory Test

  • Change from Baseline in attention and executive functions: changes on trail making test [ Time Frame: 12 months ]
    Neuropsychologic assessment: trail making test

  • Change from Baseline in attention and executive functions: changes on Stroop test [ Time Frame: 12 months ]
    Neuropsychologic assessment: Stroop I, II, III

  • Change from Baseline in complex visual perception: changes in judgement of line orientation [ Time Frame: 12 months ]
    Neuropsychologic assessment: judgement of line orientation test

  • Change from Baseline in constructive skills: changes in ability to draw a Clock drawing [ Time Frame: 12 months ]
    Neuropsychologic assessment: Drawing of a clock

  • Change from Baseline in psychiatric disease: changes in psychiatric examination [ Time Frame: 12 months ]
    psychiatric examination

  • Change from Baseline in psychiatric disease: changes on MINI [ Time Frame: 12 months ]
    Mini International Neuropsychiatric Interview

  • Change from Baseline in psychiatric disease: changes on Columbia Suicide Severity Rating Scale [ Time Frame: 12 months ]
    changes in Columbia Suicide Severity Rating Scale

  • Change from Baseline in psychiatric disease: changes on Hamilton Anxiety Scale [ Time Frame: 12 months ]
    Hamilton Anxiety Scale

  • Change from Baseline in psychiatric disease: changes on Hamilton Depression Scale [ Time Frame: 12 months ]
    Hamilton Depression Scale

  • Medical and non-medical care costs [ Time Frame: 12 months ]
    calculation of the costs by means of iMCQ and iPCQ questionnaire

  • Change from Baseline in caregiver burden [ Time Frame: 12 months ]
    questionnaire

  • Change from Baseline in Compulsive Disorders (Parkinson's Disease Impulsive-Compulsive Disorders Questionnaire (QUIP) [ Time Frame: 12 Months ]
    Parkinson's Disease Impulsive-Compulsive Disorders Questionnaire (QUIP)

  • Change from Baseline in apathy (Starkstein's Apathy Scale) [ Time Frame: 12 Months ]
    Starkstein's Apathy Scale


Estimated Enrollment: 66
Study Start Date: December 2014
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: continuous levodopa infusion
continuous intrajejunal infusion of levodopa-carbidopa
Drug: Continuous intrajejunal infusion of levodopa-carbidopa
Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)
Other Names:
  • Duodopa infusion
  • Intestinal levodopa-carbidopa infusion
Active Comparator: deep brain stimulation
Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Device: deep brain stimulation
Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Other Names:
  • DBS
  • DBS-STN

Detailed Description:

Rationale: Both Continuous intrajejunal Levodopa Infusion (CLI) and Deep Brain Stimulation (DBS) are accepted therapies for the treatment of advanced Parkinson's disease (PD). As directly comparative studies are lacking, it is unknown whether one of the therapies is more effective. Besides, CLI seems to be more expensive. To determine the optimal treatment in advanced PD, a comparative study of CLI and DBS is warranted.

Hypothesis: We hypothesize that CLI is a more expensive therapy in advanced PD than DBS and that the surplus in costs is not cost-effective with regard to benefits for the patient and caregivers in quality of life, PD symptoms and adverse events.

Objective: To realize a cost-effective treatment strategy in advanced PD. Study design: Prospective, randomized, open label multicentre trial, with two additional patient preference treatment arms ("patient preference randomized trial").

Study population: Patients with PD who, despite optimal pharmacological treatment, have severe response fluctuations, dyskinesias, painful dystonia, or bradykinesia. A total of 66 patients will be randomized, at least 120 patients will be included in the patient preference arms.

Intervention: Patients will be randomized to DBS or CLI. For DBS treatment, 2 electrodes will be implanted in the brain. The electrodes are connected to an implanted pulse generator, which will be placed subcutaneously in the subclavian area. For CLI treatment, a tube will be placed in the jejunum via a percutaneous endoscopic gastrostomy (PEG). This tube is connected to an external pump that delivers the levodopa-gel.

Main study parameters: There are 6 specified assessment visits: at baseline, and 1 week, 3, 6, 9, and 12 months after start of the study treatment. The primary health economic outcomes are the costs per unit on the PDQ-39 and the costs per QALY for the cost-effectiveness and cost-utility analyses, respectively. The EQ-5D will be applied as the utility measure. Among the secondary outcomes are quality of life, functional health, complications and adverse effects, use of care and perceptions of patients and neurologists regarding both treatments.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Idiopathic Parkinson's Disease with bradykinesia and at least two of the following signs; resting tremor, rigidity, and asymmetry;
  • Despite optimal pharmacological treatment, at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonia or bradykinesia;
  • A life expectancy of at least two years.

Exclusion Criteria:

  • Age below 18 years
  • Previous PD-neurosurgery (e.g., DBS, pallidotomy, thalamotomy);
  • Previous CLI (through a PEG-tube or Nasal Jejuna| tube);
  • Hoehn and Yahr stage 5 at the best moment during the day;
  • Other severely disabling disease;
  • Dementia or signs of severe cognitive impairment
  • Psychosis;
  • Current depression;
  • Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;
  • Contraindications for PEG surgery such as interposed organs, ascites and oesophagogastric varices, or for Duodopa;
  • Pregnancy, breastfeeding, and women of child bearing age not using a reliable method of contraception;
  • No informed consent;
  • Legally incompetent adults;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02480803

Contacts
Contact: Daniel van Poppelen, MD +31205663447 d.vanpoppelen@amc.uva.nl

Locations
Netherlands
Academic Medical Center Recruiting
Amsterdam, Noord Holland, Netherlands, 1100ZZ
Contact: Daniel van Poppelen, MD    0031205663447    invest@amc.nl   
Contact: Joke M Dijk, MD PhD    0031205669111    j.m.dijk@amc.nl   
Sponsors and Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ZonMw: The Netherlands Organisation for Health Research and Development
Investigators
Principal Investigator: Joke M Dijk, MD, PhD Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  More Information

Additional Information:
Responsible Party: J.M. Dijk, J.M. Dijk, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier: NCT02480803     History of Changes
Other Study ID Numbers: 2014_336
2014-004501-32 ( EudraCT Number )
Study First Received: May 4, 2015
Last Updated: January 31, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by J.M. Dijk, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):
Parkinson
Parkinson's Disease
Deep Brain Stimulation
levodopa-carbidopa
Duodopa
continuous intrajejunal infusion

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Levodopa
Carbidopa
Carbidopa, levodopa drug combination
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Aromatic Amino Acid Decarboxylase Inhibitors
Enzyme Inhibitors
Adjuvants, Immunologic
Immunologic Factors
Dopamine Agonists

ClinicalTrials.gov processed this record on September 21, 2017